PM Modi to visit Serum Institute of India to see the covid-19 vaccine production

The Pune based Serum Institute is currently developing 'Covishield' vaccine which is being developed by British-Swedish pharmaceutical giant AstraZeneca Plc in collaboration with Oxford University.

PM Modi to visit Serum Institute of India to see the covid-19 vaccine production
x

New Delhi: Prime Minister Narendra Modi will be visiting Serum Institute of India (SII) on November 28, that is, Saturday to closely observe the covid-19 vaccine production, an official said on Thursday. 


The Pune based Serum Institute is currently developing  'Covishield' vaccine which is being developed by British-Swedish pharmaceutical giant AstraZeneca Plc in collaboration with Oxford University.



“We have received official confirmation about the Prime Minister’s visit to Pune on November 28. The PM will visit Serum Institute which is working on the production of Covid-19 vaccine,” said Pune divisional commissioner Saurabh Rao.


Along with Serum Institute, the Prime Minister is also expected to visit Gennova Biopharmaceuticals over the weekend to see the covid-19 vaccine progress. The firm is working on an mRNA-based vaccine.



Both Serum Institute of India and Gennova Biopharmaceuticals are among the seven firms which have been granted permission by the Central Drug Standard Control Organisation to carry out pre-clinical test, examination and analysis of the coivod-19 vaccine. 



Meanwhile, in this week, PM Modi has held various meetings with state and UTs cheif ministers' to discuss the various aspects of covid-19 vaccine distribution. 


On Tuesday, during his virtual meet with Chief ministers. PM Modi said that the government is closely monitoring the covid-19 vaccine development and discussing the distribution module including the vaccination phases and price.


"Indian government is keeping a close eye on each and every development and we are in touch with everybody", pointing out, "it is not yet decided whether there will be one, two or three doses of vaccine or what will be its price," he said. 


Earlier on Tuesday, Oxford University said that its vaccine candidate can prevent 70.4 per cent people from fallin ill after the analysis of phase 3 results. 


In an official statement, the Varsity said,  "Phase 3 interim analysis including 131 Covid-19 cases indicates that the vaccine is 70.4% effective when combining data from two dosing regimens".


"In the two different dose regimens, vaccine efficacy was 90% in one, and 62% in the other," it added. 



Adar Poonawalla, CEO of Serum Institute, had said that they plan to roll our a min100 million doses of covid-19 vaccine candidate Covishield.

Next Story